Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma

Monika L Metzger; Christine Mauz-Körholz

doi:10.1111/bjh.15789

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma

Br J Haematol. 2019 Jun;185(6):1142-1157. doi: 10.1111/bjh.15789. Epub 2019 Feb 6.

Authors

Monika L Metzger¹, Christine Mauz-Körholz²

Affiliations

¹ Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
² Pädiatrische Hämatologie und Onkologie, Justus-Liebig-Universität Gießen and Medical Faculty of the Martin-Luther University of Halle, Germany.

PMID: 30729493
DOI: 10.1111/bjh.15789

Abstract

The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th 2018 in Rotterdam, the Netherlands. This review summarizes some of those presentations, as well as other current and novel antibody therapy, immune check-point inhibitors, chimeric antigen receptor T cells, cancer vaccines and cytotoxic T lymphocyte therapy.

Keywords: Hodgkin lymphoma; antibody therapy; cellular immunotherapy; chimeric antigen receptor; non-Hodgkin lymphoma; vaccine therapy.

Publication types

Review

MeSH terms

Adolescent
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor
Child
Combined Modality Therapy
Hodgkin Disease / drug therapy
Hodgkin Disease / epidemiology*
Hodgkin Disease / etiology
Humans
Immunotherapy
Lymphoma, Non-Hodgkin / epidemiology*
Lymphoma, Non-Hodgkin / etiology
Lymphoma, Non-Hodgkin / metabolism
Lymphoma, Non-Hodgkin / therapy*
Molecular Targeted Therapy*
Patient Outcome Assessment
Young Adult

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor